KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape
Journal of Clinical Oncology · 20.04.2024 · 42 (12) · 1439-1449
DOI: 10.1200/jco.23.01197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2024. Verfasst von Thomas Mühlenberg und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors, Naphthyridines. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary KIT mutations, and clonal heterogeneity of these secondary mutations represents a major treatment obstacle. KIT inhibitors used after imatinib have clinical activity, albeit with limited benefit. Ripretinib is a potent inhibitor of secondary KIT mutations in the activation loop (AL). However, clinical benefit in fourth line remains limited and the molecular mechanisms of ripretinib resistance are largely unknown. PATIENTS AND METHODS Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models and in silico modeling. RESULTS GISTs progressing on ripretinib were enriched for secondary mutations in the ATP-binding pocket (AP), which frequently occur in cis with preexisting AL mutations, resulting in highly resistant AP/AL genotypes. AP/AL mutations were rarely observed in a cohort of progressing GIST samples from the preripretinib era but represented 50% of secondary KIT mutations in patients with tumors resistant to ripretinib. In GIST cell lines harboring secondary KIT AL mutations, the sole genomic escape mechanisms during ripretinib drug selection were AP/AL mutations. Ripretinib and sunitinib synergize against mixed clones with secondary AP or AL mutants but do not suppress clones with AP/AL genotypes. CONCLUSION Our findings underscore that KIT remains the central oncogenic driver even in late lines of GIST therapy. KIT-inhibitor combinations may suppress resistance because of secondary KIT mutations. However, the emergence of KIT AP/AL mutations after ripretinib treatment calls for new strategies in the development of next-generation KIT inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany.
- DKTK partner site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany.
- Department of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.
- Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany.
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Department of Hematology and Oncology, Fox Chase Cancer Center, Temple Health System, University, Philadelphia, PA.
ORCID-Profile: Thomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, Benjamin S Fletcher, Alina Teuber, Isabella Klooster, Meijun Lundberg, Jonas Lategahn, Margaret von Mehren, Alicia Isabell Tüns, Jason K Sicklick, Mehdi Brahmi, Hans-Ulrich Schildhaus, Michael C Heinrich, Chandrajit P Raut, Wen-Bin Ou, Adrian Marino-Enriquez, Suzanne George, Daniel Rauh, Jonathan A Fletcher, Sebastian Bauer
Förderung
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Mühlenberg, T., Falkenhorst, J., Schulz, T., Fletcher, B. S., Teuber, A., Krzeciesa, D., Klooster, I., Lundberg, M., Wilson, L., Lategahn, J., von Mehren, M., Grunewald, S., Tüns, A. I., Wardelmann, E., Sicklick, J. K., Brahmi, M., Serrano, C., Schildhaus, H. U., Sievers, S., …, & Bauer, S. (2024). KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape. Journal of Clinical Oncology, 42(12), 1439-1449. https://doi.org/10.1200/jco.23.01197
Vancouver
Mühlenberg T, Falkenhorst J, Schulz T, Fletcher BS, Teuber A, Krzeciesa D, et al. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape. Journal of Clinical Oncology. 2024;42(12):1439-1449. doi:10.1200/jco.23.01197
BibTeX
@article{Mhlenberg2024,
author = {Mühlenberg, Thomas and Falkenhorst, Johanna and Schulz, Tom and Fletcher, Benjamin S and Teuber, Alina and Krzeciesa, Dawid and Klooster, Isabella and Lundberg, Meijun and Wilson, Lydia and Lategahn, Jonas and von Mehren, Margaret and Grunewald, Susanne and Tüns, Alicia Isabell and Wardelmann, Eva and Sicklick, Jason K and Brahmi, Mehdi and Serrano, César and Schildhaus, Hans-Ulrich and Sievers, Sonja and Treckmann, Jürgen and Heinrich, Michael C and Raut, Chandrajit P and Ou, Wen-Bin and Marino-Enriquez, Adrian and George, Suzanne and Rauh, Daniel and Fletcher, Jonathan A and Bauer, Sebastian},
title = {KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {12},
pages = {1439--1449},
doi = {10.1200/jco.23.01197}
}
EUVIMED